Aptus Pharma Limited reported a sharp increase in profitability for the first half of FY27, with net profit rising 190% year-on-year to ₹5.07 crore. The pharmaceutical distributor recorded revenue from operations of ₹48.92 crore, nearly tripling from the ₹14.38 crore logged in the corresponding period last year.

The company’s EBITDA stood at ₹7.68 crore for the half-year ended September 30, 2026, reflecting strong operational momentum as it transitions from a regional player to a national entity. The Board of Directors approved these unaudited financial results during a meeting held on October 20, 2026.

Financial Performance Highlights

The following table summarizes the key financial metrics for the half-year ended September 30, 2026, compared to the same period in the previous fiscal year:

Note: Figures converted from source data in lakhs for clarity where necessary; source data primarily in lakhs.

What the Numbers Show

A divergence between top-line growth and balance sheet health is evident. While revenue grew significantly, operating cash flow remained negative at (₹6.80 crore) for the half-year, driven by a substantial increase in trade receivables which rose to ₹28.64 crore from ₹18.76 crore at the end of FY26. This suggests that while sales are expanding rapidly, cash collection cycles are lengthening, potentially indicating increased credit exposure or aggressive distribution terms to fuel growth.

Strategic Expansion and Capital Structure

Management highlighted plans to expand geographic coverage to 46% across India by March 2027, aiming for pan-India presence by March 2029. The company is also pursuing long-term goals such as developing manufacturing capabilities and entering global markets.

On the capital front, Aptus Pharma issued 102.90 lakh bonus equity shares in May 2026 in a 3:2 ratio, increasing outstanding shares to 171.50 lakh. Additionally, shareholders approved a preferential issue of 16.02 lakh shares at ₹280 per share, aggregating to ₹44.88 crore, subject to regulatory approvals. As of the board meeting date, no allotment has occurred under this preferential issue.

Regulatory and Audit Details

The financial statements were reviewed by ABKB & Co., Chartered Accountants, who issued an unqualified limited review report. The trading window for designated persons opened on October 23, 2026, following the disclosure of results.

Aptus Pharma Limited has closed its trading window for dealing in company securities starting October 1, 2026. The closure remains in effect until the completion of 48 hours after the declaration of financial results for the half year ended September 30, 2026.

Insider Trading Compliance

The decision is made pursuant to the Company's Code of Conduct for Prohibition of Insider Trading. This measure ensures compliance with regulatory standards regarding the handling of unpublished price-sensitive information during the period leading up to the earnings announcement.

Key Details of Closure

The notice was submitted to The BSE Ltd on September 28, 2026. The Managing Director, Tejash Hathi, signed the communication digitally to inform the exchange of the window closure. This procedural step restricts designated persons from trading in the company's shares during the blackout period to prevent potential misuse of confidential financial data.